S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 1-11, 2019.
Article
in En
| WPRIM
| ID: wpr-719724
Responsible library:
WPRO
ABSTRACT
PURPOSE:
We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients. MATERIALS ANDMETHODS:
Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m2/day on days 1-14 plus docetaxel 35 mg/m2on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m2/day on days 1-14 plus cisplatin 60 mg/m2on day 1) every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate.RESULTS:
Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was approved based on the CLASSIC study, itwas decided to close the study early. With a median follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not significantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4 adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned treatment.CONCLUSION:
Our findings suggest that SP or DS is an effective and tolerable option for patients with curatively resected stage III gastric cancer.Key words
Full text:
1
Index:
WPRIM
Main subject:
Stomach Neoplasms
/
Follow-Up Studies
/
Cisplatin
/
Chemotherapy, Adjuvant
/
Disease-Free Survival
/
Mucositis
/
Hand-Foot Syndrome
/
Capecitabine
/
Gastrectomy
/
Anemia
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Cancer Research and Treatment
Year:
2019
Type:
Article